Chattaraj Aditi, Mishra Vijay, Mishra Yachana
School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab 144411 India.
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411 India.
Indian J Microbiol. 2025 Mar;65(1):538-553. doi: 10.1007/s12088-024-01367-7. Epub 2024 Aug 8.
One of the most serious gynecological diseases in the world is ovarian cancer (OC). These days, the majority of patients are identified at an advanced stage (III or IV), with subpar diagnosis resulting in a return of the illness. Conventional medicines fail as a result of issues with early illness identification and treatment processing, including issues with dosage delivery, side effects, and treatment resistance. The carbon nanotube (CNT)-based drug delivery systems for specific OC therapy are highlighted in this review. These systems have several advantages against free drugs, including nontoxicity, biological compatibility, high biodegradability, increased therapeutic impact, and non-inflammatory effects. Crucially, functionalized CNTs with particular ligands like cancer antigen (CA125), Human epididymis protein 4 (HE4), Mucin 1, and folic acid (FA) allow for selective targeting of OC and ultimately increase therapeutic potential in comparison to their nonfunctionalized counterparts. This review focused on the potential applications of CNTs in the detection and treatment of OC, as well as their present status and future clinical developments.
卵巢癌（OC）是世界上最严重的妇科疾病之一。如今，大多数患者在晚期（III期或IV期）才被确诊，欠佳的诊断导致疾病复发。由于早期疾病识别和治疗过程存在问题，包括给药剂量、副作用和治疗耐药性等问题，传统药物治疗效果不佳。本综述重点介绍了用于特定卵巢癌治疗的基于碳纳米管（CNT）的药物递送系统。这些系统相对于游离药物具有若干优势，包括无毒性、生物相容性、高生物降解性、增强的治疗效果和无炎症作用。至关重要的是，与未功能化的碳纳米管相比，带有癌症抗原（CA125）、人附睾蛋白4（HE4）、粘蛋白1和叶酸（FA）等特定配体的功能化碳纳米管能够实现对卵巢癌的选择性靶向，并最终提高治疗潜力。本综述重点关注了碳纳米管在卵巢癌检测和治疗中的潜在应用，以及它们的现状和未来的临床发展。
